155 related articles for article (PubMed ID: 2004812)
1. Physicochemical and biological properties of purified Escherichia coli Shiga-like toxin II variant.
MacLeod DL; Gyles CL; Valdivieso-Garcia A; Clarke RC
Infect Immun; 1991 Apr; 59(4):1300-6. PubMed ID: 2004812
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of the Shiga-like toxin produced by Escherichia coli associated with porcine edema disease.
Gannon VP; Gyles CL
Vet Microbiol; 1990 Jul; 24(1):89-100. PubMed ID: 2219668
[TBL] [Abstract][Full Text] [Related]
3. Escherichia coli cytotoxins and enterotoxins.
Gyles CL
Can J Microbiol; 1992 Jul; 38(7):734-46. PubMed ID: 1393838
[TBL] [Abstract][Full Text] [Related]
4. Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine.
Weinstein DL; Jackson MP; Samuel JE; Holmes RK; O'Brien AD
J Bacteriol; 1988 Sep; 170(9):4223-30. PubMed ID: 3045088
[TBL] [Abstract][Full Text] [Related]
5. Evidence that proteolytic separation of Shiga-like toxin type IIv A subunit into A1 and A2 subunits is not required for toxin activity.
Samuel JE; Gordon VM
J Biol Chem; 1994 Feb; 269(7):4853-9. PubMed ID: 7906271
[TBL] [Abstract][Full Text] [Related]
6. Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice.
Melton-Celsa AR; Darnell SC; O'Brien AD
Infect Immun; 1996 May; 64(5):1569-76. PubMed ID: 8613362
[TBL] [Abstract][Full Text] [Related]
7. Transcription of the Shiga-like toxin type II and Shiga-like toxin type II variant operons of Escherichia coli.
Sung LM; Jackson MP; O'Brien AD; Holmes RK
J Bacteriol; 1990 Nov; 172(11):6386-95. PubMed ID: 2228965
[TBL] [Abstract][Full Text] [Related]
8. An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine.
Gordon VM; Whipp SC; Moon HW; O'Brien AD; Samuel JE
Infect Immun; 1992 Feb; 60(2):485-90. PubMed ID: 1730480
[TBL] [Abstract][Full Text] [Related]
9. Immunization of pigs with a purified Shiga-like toxin II variant toxoid.
MacLeod DL; Gyles CL
Vet Microbiol; 1991 Nov; 29(3-4):309-18. PubMed ID: 1837635
[TBL] [Abstract][Full Text] [Related]
10. Purification and some properties of a Vero toxin 2 (Shiga-like toxin II) variant (SLT-IIva) of Escherichia coli isolated from infantile diarrhea.
Ohmura M; Cao C; Karasawa T; Okuda J; Kurazono H; Gannon VP; Gyles CL; Takeda Y
Microb Pathog; 1993 Nov; 15(5):399-405. PubMed ID: 8015420
[TBL] [Abstract][Full Text] [Related]
11. Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome.
Rüssmann H; Schmidt H; Heesemann J; Caprioli A; Karch H
J Med Microbiol; 1994 May; 40(5):338-43. PubMed ID: 7909850
[TBL] [Abstract][Full Text] [Related]
12. Cloning and sequencing of a Shiga-like toxin II-related gene from Escherichia coli O157:H7 strain 7279.
Meyer T; Karch H; Hacker J; Bocklage H; Heesemann J
Zentralbl Bakteriol; 1992 Jan; 276(2):176-88. PubMed ID: 1559006
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding subunits by using site-directed mutagenesis.
Jackson MP; Wadolkowski EA; Weinstein DL; Holmes RK; O'Brien AD
J Bacteriol; 1990 Feb; 172(2):653-8. PubMed ID: 2404947
[TBL] [Abstract][Full Text] [Related]
14. Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity.
Perera LP; Samuel JE; Holmes RK; O'Brien AD
J Bacteriol; 1991 Feb; 173(3):1151-60. PubMed ID: 1991714
[TBL] [Abstract][Full Text] [Related]
15. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies.
Downes FP; Barrett TJ; Green JH; Aloisio CH; Spika JS; Strockbine NA; Wachsmuth IK
Infect Immun; 1988 Aug; 56(8):1926-33. PubMed ID: 3294179
[TBL] [Abstract][Full Text] [Related]
16. Construction of recombinant Shiga-like toxin-IIv (SLT-IIv) and its use in monitoring the SLT-IIv antibody status of pigs.
Franke S; Gunzer F; Wieler LH; Baljer G; Karch H
Vet Microbiol; 1995 Jan; 43(1):41-52. PubMed ID: 7716883
[TBL] [Abstract][Full Text] [Related]
17. Evidence that the A2 fragment of Shiga-like toxin type I is required for holotoxin integrity.
Austin PR; Jablonski PE; Bohach GA; Dunker AK; Hovde CJ
Infect Immun; 1994 May; 62(5):1768-75. PubMed ID: 8168939
[TBL] [Abstract][Full Text] [Related]
18. In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and role of the B subunit in localization and cytotoxic activity.
Weinstein DL; Jackson MP; Perera LP; Holmes RK; O'Brien AD
Infect Immun; 1989 Dec; 57(12):3743-50. PubMed ID: 2807546
[TBL] [Abstract][Full Text] [Related]
19. Hybridization of Escherichia coli producing Shiga-like toxin I, Shiga-like toxin II, and a variant of Shiga-like toxin II with synthetic oligonucleotide probes.
Brown JE; Sethabutr O; Jackson MP; Lolekha S; Echeverria P
Infect Immun; 1989 Sep; 57(9):2811-4. PubMed ID: 2668189
[TBL] [Abstract][Full Text] [Related]
20. Purification and characterization of an Escherichia coli Shiga-like toxin II variant.
MacLeod DL; Gyles CL
Infect Immun; 1990 May; 58(5):1232-9. PubMed ID: 2182539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
